Masahiro Morise

Masahiro Morise

Auto-generated profile, based on publicly available information

Masahiro Morise

Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8560, Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Lung Cancer
Verified
Journal Article
Closed access
KNKazuhiko Nakagawa
Kazuhiko Nakagawa
THToyoaki Hida
Toyoaki Hida
HNHiroshi Nokihara
Hiroshi Nokihara
MMMasahiro Morise
Masahiro Morise
KAKoichi Azuma
Koichi Azuma
TTTomohide Tamura
Tomohide Tamura

1 February 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
EIEiji Iwama
Eiji Iwama
YZYoshitaka Zenke
Yoshitaka Zenke
SSShunichi Sugawara
Shunichi Sugawara
HDHaruko Daga
Haruko Daga
MMMasahiro Morise
Masahiro Morise
IOIsamu Okamoto
Isamu Okamoto

10 January 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
AHAkito Hata
Akito Hata
IOIsamu Okamoto
Isamu Okamoto
NINaoki Inui
Naoki Inui
MOMorihito Okada
Morihito Okada
MMMasahiro Morise
Masahiro Morise
TTTomohide Tamura
Tomohide Tamura
PURPOSE: We evaluated the efficacy and safety of fosnetupitant (FosNTP) versus fosaprepitant (FosAPR) for preventing highly emetogenic chemotherapy-induced nausea and vomiting. This phase III study was the first head-to-head comparison between two different neurokinin-1 receptor antagonists in combination with palonosetron and dexamethasone. PATIENTS AND METHODS: Patients scheduled to receive cisplatin-based chemotherapy were randomly assigned 1:1 to FosNTP 235 mg or FosAPR 150 mg in combination with palonosetron 0.75 mg and dexamethasone. The primary end point was overall (0-120 hours) complete response (CR; no emetic event and no rescue medication) rate, stratified by sex and age category, to show the noninferiority of FosNTP to FosAPR (noninferiority margin, –10% for the difference in the overall CR rate). RESULTS: Overall, 795 patients were randomly assigned, of whom 785 received the study drug (FosNTP [N = 392] v FosAPR [N = 393]) and were evaluated for efficacy and safety. The overall CR rate was 75.2% versus 71.0%, respectively (Mantel-Haenszel common risk difference, 4.1%; 95% CI, –2.1% to 10.3%), demonstrating noninferiority of FosNTP to FosAPR. The CR rates in the acute (0-24 hours), delayed (24-120 hours), and beyond delayed (120-168 hours) phases, and at 0-168 hours were 93.9% versus 92.6%, 76.8% versus 72.8%, 86.5% versus 81.4%, and 73.2% versus 66.9%, respectively. The incidence rates of treatment-related adverse events with FosNTP versus FosAPR were 22.2% versus 25.4%, whereas adverse events or treatment-related adverse events relevant to injection site reactions were 11.0% versus 20.6% ( P < .001) and 0.3% versus 3.6% ( P < .001), respectively. CONCLUSION: FosNTP demonstrated noninferiority to FosAPR, with a favorable safety profile and lower risk for injection site reactions. Thus, FosNTP is valuable in the prophylaxis of acute, delayed, and beyond delayed chemotherapy-induced nausea and vomiting.

17 December 2021 in Future Oncology
Verified
Journal Article
Open access
ESEgbert F Smit
Egbert F Smit
CDChristophe Dooms
Christophe Dooms
JRJo Raskin
Jo Raskin
Ernest NadalErnest Nadal
Ernest Nadal
LTLye M Tho
Lye M Tho
YWYI-LONG WU
YI-LONG WU
MET amplification (METamp), a mechanism of acquired resistance to EGFR tyrosine kinase inhibitors, occurs in up to 30% of patients with non-small-cell lung cancer (NSCLC) progressing on first-line ... Plain language summary Osimertinib is used to treat a type of lung cancer that has specific changes (mutations) in a gene called EGFR. Although tumors will usually shrink (respond) during treatment...

1 June 2021 in ESMO Open
Verified
Journal Article
Open access
KIK. Ito
K. Ito
MMM. Morise
M. Morise
KWK. Wakuda
K. Wakuda
OHO. Hataji
O. Hataji
TST. Shimokawaji
T. Shimokawaji
HSH. Saka
H. Saka
FLAURA, the prospective trial of osimertinib as a first-line therapy compared with first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), did not show superior survival benefit for osimertinib in either the subgroup of Asians or the subgroup with the L858R mutation. In addition, the superiority of osimertinib compared with second-generation EGFR-TKI is thus far unclear. We reviewed the clinical data of all consecutive patients who were treated with osimertinib or afatinib as first-line therapy between May 2016 and October 2019 from 15 institutions in Japan. We defined the groups based on first-line EGFR-TKI as the afatinib group and the osimertinib group. Outcomes included time to discontinuation of any EGFR-TKI (TD-TKI), overall survival (OS), and time to treatment failure, with propensity score analysis carried out as an exploratory analysis in the survival and subgroup analyses. A total of 554 patients were enrolled. Data on 326 patients in the osimertinib group, and 224 patients in the afatinib group were analyzed. TD-TKI adjusted by propensity score in the afatinib and osimertinib groups was 18.6 months (95% confidence interval 15.8 to 22.0) and 20.5 months (95% confidence interval 13.8 to not reached), respectively, without significant difference (P = 0.204). OS adjusted by propensity score favored the afatinib group with a significant difference (P = 0.018). Subgroup analysis with propensity score showed that patients with L858R and without brain metastasis had superior survival benefit with afatinib compared with osimertinib (P < 0.001). TD-TKI in the afatinib group was not significantly prolonged compared with the osimertinib group in the practical data. In the exploratory analysis of patients with L858R-mutated non-small-cell lung cancer without brain metastasis, afatinib showed more benefit in OS over osimertinib.

1 September 2020 in Respiratory Investigation
Verified
Journal Article
Closed access
KSKoji Sakamoto
Koji Sakamoto
JFJun Fukihara
Jun Fukihara
MMMasahiro Morise
Masahiro Morise
NHNaozumi Hashimoto
Naozumi Hashimoto